Andrew J Gunn1, Winston B Joe2, Aliaksei Salei3, Husameddin El Khudari3, Khalid H Mahmoud3, Eric Bready3, Eric M Keasler3, Patrick P Patten3, Jennifer B Gordetsky4, Soroush Rais-Bahrami5, Ahmed K Abdel Aal3. 1. Division of Vascular and Interventional Radiology, Department of Radiology, University of Alabama at Birmingham, 619 19th St S, Birmingham, AL, 35249, UK. agunn@uabmc.edu. 2. University of Alabama at Birmingham School of Medicine, 1720 2nd Ave. S., Birmingham, AL, 35294, UK. 3. Division of Vascular and Interventional Radiology, Department of Radiology, University of Alabama at Birmingham, 619 19th St S, Birmingham, AL, 35249, UK. 4. Department of Pathology, University of Alabama at Birmingham, 619 19th St S, Birmingham, AL, 35249, UK. 5. Department of Urology, University of Alabama at Birmingham, 1720 2nd Ave. S., Birmingham, AL, 35294, UK.
Abstract
PURPOSE: The use of percutaneous cryoablation for T1b (4.1-7.0 cm) renal cell carcinoma, has not yet been widely adopted. The purpose of this study was to describe our experience in the cryoablation of stage T1b tumors with an emphasis on safety, technical results, and clinical outcomes. MATERIALS AND METHODS: A retrospective review of hospital records identified 37 patients who underwent cryoablation for T1b lesions from 2008 to 2018. Patient demographics, comorbidities, tumor characteristics, technical parameters, and outcomes were recorded and analyzed. Recurrence-free, overall, and cancer-specific survival rates were estimated using the Kaplan-Meier method. RESULTS: Thirty-seven patients (22 males, 15 females; mean age 66.5 ± 11.3) with 37 T1b tumors (mean diameter 47.3 ± 6.3 mm) were included. A median of 3 probes were used (range: 1-7). Angio-embolization was used in 3/37 (8.1%) and 2/37 patients (5.4%) required hydrodissection. The mean number of total cryoablation procedures for each patient was 1.5 (median 1; range: 1-4). Technical success was achieved in 88.2% of patients. Recurrence-free survival was 96.5%, 86.1%, and 62.6% at 1, 2, and 3 years respectively. Cancer-specific survival was 100% at 1, 2, and 3 years respectively. Overall survival was 96.7%, 91.8%, and 77.6% at 1, 2, and 3 years respectively. Complications classified as CIRSE grade 2 or higher occurred in 6/37 (16.2%) patients. CONCLUSION: T1b cryoablation is associated with high rates of technical success, excellent cancer-specific survival, and an acceptable safety profile. LEVEL OF EVIDENCE: Level 4, Case Series.
PURPOSE: The use of percutaneous cryoablation for T1b (4.1-7.0 cm) renal cell carcinoma, has not yet been widely adopted. The purpose of this study was to describe our experience in the cryoablation of stage T1b tumors with an emphasis on safety, technical results, and clinical outcomes. MATERIALS AND METHODS: A retrospective review of hospital records identified 37 patients who underwent cryoablation for T1b lesions from 2008 to 2018. Patient demographics, comorbidities, tumor characteristics, technical parameters, and outcomes were recorded and analyzed. Recurrence-free, overall, and cancer-specific survival rates were estimated using the Kaplan-Meier method. RESULTS: Thirty-seven patients (22 males, 15 females; mean age 66.5 ± 11.3) with 37 T1b tumors (mean diameter 47.3 ± 6.3 mm) were included. A median of 3 probes were used (range: 1-7). Angio-embolization was used in 3/37 (8.1%) and 2/37 patients (5.4%) required hydrodissection. The mean number of total cryoablation procedures for each patient was 1.5 (median 1; range: 1-4). Technical success was achieved in 88.2% of patients. Recurrence-free survival was 96.5%, 86.1%, and 62.6% at 1, 2, and 3 years respectively. Cancer-specific survival was 100% at 1, 2, and 3 years respectively. Overall survival was 96.7%, 91.8%, and 77.6% at 1, 2, and 3 years respectively. Complications classified as CIRSE grade 2 or higher occurred in 6/37 (16.2%) patients. CONCLUSION: T1b cryoablation is associated with high rates of technical success, excellent cancer-specific survival, and an acceptable safety profile. LEVEL OF EVIDENCE: Level 4, Case Series.
Authors: Maxine Sun; Rodolphe Thuret; Firas Abdollah; Giovanni Lughezzani; Jan Schmitges; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Anna J Moreland; Timothy J Ziemlewicz; Sara L Best; J Louis Hinshaw; Meghan G Lubner; Marci L Alexander; Christopher L Brace; Douglas R Kitchin; Sean P Hedican; Stephen Y Nakada; Fred T Lee; E Jason Abel Journal: J Endourol Date: 2014-07-02 Impact factor: 2.942
Authors: Aaron W P Maxwell; Grayson L Baird; Jason D Iannuccilli; William W Mayo-Smith; Damian E Dupuy Journal: Radiology Date: 2016-11-22 Impact factor: 11.105
Authors: Thomas D Atwell; Rickey E Carter; Grant D Schmit; Carrie M Carr; Stephen A Boorjian; Timothy B Curry; R Houston Thompson; A Nicholas Kurup; Adam J Weisbrod; George K Chow; Bradley C Leibovich; Matthew R Callstrom; David E Patterson Journal: J Vasc Interv Radiol Date: 2011-10-28 Impact factor: 3.464
Authors: Phillip M Pierorazio; Michael H Johnson; Hiten D Patel; Stephen M Sozio; Ritu Sharma; Emmanuel Iyoha; Eric B Bass; Mohamad E Allaf Journal: J Urol Date: 2016-05-06 Impact factor: 7.450
Authors: Steven Campbell; Robert G Uzzo; Mohamad E Allaf; Eric B Bass; Jeffrey A Cadeddu; Anthony Chang; Peter E Clark; Brian J Davis; Ithaar H Derweesh; Leo Giambarresi; Debra A Gervais; Susie L Hu; Brian R Lane; Bradley C Leibovich; Philip M Pierorazio Journal: J Urol Date: 2017-05-04 Impact factor: 7.450
Authors: Sara L Best; Samuel K Park; Ramy F Youssef; Ramy F Yaacoub; Ephrem O Olweny; Yung K Tan; Clayton Trimmer; Jeffrey A Cadeddu Journal: J Urol Date: 2012-02-14 Impact factor: 7.450
Authors: B M Aarts; W Prevoo; M A J Meier; A Bex; R G H Beets-Tan; E G Klompenhouwer; F M Gómez Journal: Cardiovasc Intervent Radiol Date: 2020-02-12 Impact factor: 2.740